AhR |
Hepatic fibrosis and impaired immune system |
129xC57BL/6 |
Disruption of exon 1 leads to 50% mortality in perinatal period Resistant to TCDD toxicity Reduced retinoic acid metabolism |
(42)
|
|
Viable, fertile but with hepatic defects |
129xC57BL/6 |
Disruption of exon 2 |
(43)
|
|
Viable, fertile |
129xC57BL/6 |
Disruption of exon 2; lacZ reporter Resistant to BaP carcinogenicity
|
(41)
|
ARNT |
Embryonic lethal |
129xC57BL/6 |
Disruption of bHLH domain Defects in neural tube closure, embryo rotation |
(46)
|
|
Embryonic lethal |
Not stated |
Disruption of bHLH domain Defective angiogenesis of yolk sac and branchial arches, stunted development |
(45)
|
|
Loss of induction via AhR in liver |
129xC57BL/6 |
Disruption of exon 6 Conditional deletion (Mx-1-Cre) |
(47)
|
Nrf2 |
None |
129xC57BL/6 |
Disruption of exons 4,5; lacZ reporter Increased sensitivity to acetaminophen
|
(49)
|
|
Develop autoimmune nephritis >60 weeks old |
129xICR |
Disruption of exon 5; lacZ reporter Increased sensitivity to acetaminophen
|
(50)
|
AhR/Nrf2 |
Nonea |
129xC57BL/6xICR |
Response to 3MC and BHA abolished |
(55)
|
PPARα |
None |
129xC57BL/6 |
Disruption of exon 8 Lack of response to peroxisome proliferators |
(57)
|
PPARδ |
Reduced growth; Smaller gonadal adipose stores; Reduced brain myelination; Increased epidermal hyperplastic response to TPA |
129xC57BL/6b |
Disruption of last exon |
(59)
|
PPARγ |
Embryonic lethal |
Not stated |
Disruption of zinc finger coding region |
(61)
|
|
Altered cholesterol homeostasis |
129xC57BL/6 |
Conditional deletion (macrophages) |
(62)
|